Extensive analysis of signaling pathway molecules in breast cancer: association with clinicopathological characteristics
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 605490902 | ||
| 003 | CHVBK | ||
| 005 | 20210128100507.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 210128e20150601xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1007/s10147-014-0753-8 |2 doi |
| 035 | |a (NATIONALLICENCE)springer-10.1007/s10147-014-0753-8 | ||
| 245 | 0 | 0 | |a Extensive analysis of signaling pathway molecules in breast cancer: association with clinicopathological characteristics |h [Elektronische Daten] |c [Rie Horii, Masaaki Matsuura, Shingo Dan, Masaru Ushijima, Natsue Uehiro, Akiko Ogiya, Naoko Honma, Yoshinori Ito, Takuji Iwase, Takao Yamori, Futoshi Akiyama] |
| 520 | 3 | |a Background: The aim of this study was to extensively analyze the signaling pathway molecules in breast cancer and to explore candidate biomarkers for clinicopathological relevance. Methods: We assessed the expression of key factors in cell signaling, namely p-AKT, cyclin D1, P27, p-p70S6K, p-4EBP1, and p-MAPK/ERK, within 338 invasive breast cancer patients. These factors were immunohistochemically examined in tumor tissues and assessed by staining score. Staining scores were analyzed by a clustering method to devise a new classification based on pathway activity. We investigated the relationships among staining scores, the clustering classification, and patient characteristics. Results: The proportion of patients displaying high expression levels were as fol lows: p-AKT, 75%; cyclin D1, 12%; P27, 53%; p-p70S6K, 37%; p-4EBP1, 19%; and p-MAPK/ERK, 3%. Patients were classified into two groups on the basis of staining scores. Group 1 (39%) included more positive cases for p-4EBP1, p-MAPK/ERK, and p-p70S6K and fewer positive cases for P27 and cyclin D1 than Group 2 (61%). The clustering classification was significantly related to subgrouping by hormone receptor and HER2 (P<0.001), nuclear grade (P<0.001) and histological subtype (P=0.034). A strong positive correlation was identified between p-AKT and P27, cyclin D1 and P27, p-p70S6K and p-4EBP1, p-p70S6K and p-MAPK/ERK, and between p-4EBP1 and p-MAPK/ERK. Levels of p-p70S6K were significantly related to recurrence in both univariate (RR=0.75, P<0.001) and multivariate (RR=0.71, P=0.049) analyses. Conclusions: The present study helps us to understand the characteristics of signaling pathway status in breast cancers. Moreover, p-p70S6K expression may be of use in predicting clinical outcome. | |
| 540 | |a Japan Society of Clinical Oncology, 2014 | ||
| 690 | 7 | |a Breast cancer |2 nationallicence | |
| 690 | 7 | |a Pathology |2 nationallicence | |
| 690 | 7 | |a Classification |2 nationallicence | |
| 690 | 7 | |a p-p70S6K |2 nationallicence | |
| 690 | 7 | |a Signaling pathway |2 nationallicence | |
| 690 | 7 | |a Survival |2 nationallicence | |
| 700 | 1 | |a Horii |D Rie |u Department of Pathology, Cancer Institute, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, 135-8550, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Matsuura |D Masaaki |u Department of Cancer Genomics, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Dan |D Shingo |u Department of Molecular Pharmacology, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Ushijima |D Masaru |u Bioinformatics Group, Genome Center, Japanese Foundation for Cancer Research, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Uehiro |D Natsue |u Breast Oncology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Ogiya |D Akiko |u Breast Oncology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Honma |D Naoko |u Department of Pathology, Cancer Institute, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, 135-8550, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Ito |D Yoshinori |u Breast Oncology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Iwase |D Takuji |u Breast Oncology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Yamori |D Takao |u Department of Molecular Pharmacology, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Akiyama |D Futoshi |u Department of Pathology, Cancer Institute, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, 135-8550, Tokyo, Japan |4 aut | |
| 773 | 0 | |t International Journal of Clinical Oncology |d Springer Japan |g 20/3(2015-06-01), 490-498 |x 1341-9625 |q 20:3<490 |1 2015 |2 20 |o 10147 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s10147-014-0753-8 |q text/html |z Onlinezugriff via DOI |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 900 | 7 | |a Metadata rights reserved |b Springer special CC-BY-NC licence |2 nationallicence | |
| 908 | |D 1 |a research-article |2 jats | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-springer | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1007/s10147-014-0753-8 |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Horii |D Rie |u Department of Pathology, Cancer Institute, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, 135-8550, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Matsuura |D Masaaki |u Department of Cancer Genomics, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Dan |D Shingo |u Department of Molecular Pharmacology, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Ushijima |D Masaru |u Bioinformatics Group, Genome Center, Japanese Foundation for Cancer Research, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Uehiro |D Natsue |u Breast Oncology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Ogiya |D Akiko |u Breast Oncology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Honma |D Naoko |u Department of Pathology, Cancer Institute, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, 135-8550, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Ito |D Yoshinori |u Breast Oncology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Iwase |D Takuji |u Breast Oncology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Yamori |D Takao |u Department of Molecular Pharmacology, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Akiyama |D Futoshi |u Department of Pathology, Cancer Institute, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, 135-8550, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t International Journal of Clinical Oncology |d Springer Japan |g 20/3(2015-06-01), 490-498 |x 1341-9625 |q 20:3<490 |1 2015 |2 20 |o 10147 | ||